News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026, at 9:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and Chair of the Management Board - Helen Giza Chief Financial Officer - Martin Fischer Investor Relations - Dominik Heger Full Conference Call Transcript Operator: Ladies and gentlemen, welcome to the report on Second Quarter 2026 Earnings Release and …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer …
Earnings Call Insights: Fresenius Medical Care (FMS) Q2 2026 MANAGEMENT VIEW * "We continued our strong start to the year, delivering another quarter of highly profitable growth" (Chair of Management Board & CEO Helen Giza). She said operating income growth "accelerated to 23%" and …
This article first appeared on GuruFocus. Revenue: Solid organic group revenue growth of 5% in Q2, with a 4% increase at constant currency. Operating Income: Increased significantly by 23% at constant currency, with growth accelerating and in line with planned phasing for 2026. Operating …
Researcher looking through microscope ©Adobe Stock Images Fresenius Medical Care (NYSE:FMS) shares fell 8.0% to €41.285 during Tuesday's trading session as investors looked beyond better-than-expected second-quarter results and focused instead on continued weakness in U.S. patient treatment volumes. Although the dialysis provider exceeded analyst …
* Fresenius Medical Care press release [https://seekingalpha.com/pr/20604629-fresenius-medical-care-accelerates-income-growth-to-23-percent-in-the-second-quarter-of-2026] (FMS [https://seekingalpha.com/symbol/FMS]): Q2 GAAP EPS of EUR0.81. * Revenue of EUR4.86B. MORE ON FRESENIUS MEDICAL CARE * Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth [https://seekingalpha.com/article/4923734-fresenius-medical-care-more-favorable-patient-outcomes-will-drive-growth] * Fresenius Medical: High Yield, Utilities-Like Stock At Valuation …
BAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, has appointed Cassie McLean (48) as a member of the Management Board, effective 1 August …
BEACON-US research initiative is evaluating the clinical outcomes and patient experiences of high-volume hemodiafiltration in routine U.S. clinical practice across diverse patient populations Fresenius Medical Care expands access to the therapy across the U.S. building on two decades of evidence and treatment from over …
This article first appeared on GuruFocus. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Quest Diagnostics Inc (NYSE:DGX) reported a strong revenue growth of over 10% in the second …
Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings Available within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care's FDA 510(k)-cleared software platform for kidney replacement therapy in the United States Aggregates existing therapy …
Search by ticker symbol or company name and select a result to open its chart.